Iotrolan is a nonionic, dimeric contrast medium designed for high-quality radiographic imaging, especially in myelography and intrathecal procedures. It was developed in the late 1980s to address the limitations of earlier ionic contrast agents. Researchers aimed to create a medium with lower osmolality to improve patient safety and comfort. Iotrolan’s molecular structure provides excellent stability and reduces the risk of neurotoxicity. Its introduction marked a significant improvement in spinal imaging due to clearer visualization and fewer adverse reactions. Over time, it became a preferred option for delicate neurological studies. Today, iotrolan remains valued for its safety profile and diagnostic effectiveness in specialized radiologic applications.
